Skip to main content

From the helm: Proteomics International (ASX:PIQ), Dr. Richard Lipscombe, Managing Director

Bell Direct
July 7, 2025

In this episode of From the helm, Bell Financial Group’s Grady Wulff speaks with Proteomics International Laboratories (ASX: PIQ) CEO, Dr. Richard Lipscombe, about the company’s ground breaking work in predictive diagnostics and the global opportunity for its world-first blood tests.

In this video, Dr. Lipscombe covers:
·      (0:47): An overview of PIQ and its FY26 goals
·      (1:38): The significance of three world-first blood tests
·      (5:26): The global addressable markets for these conditions
·      (6:25): Clinical trial progress and commercialisation roadmap
·      (8:14): How the diagnostic tests work and deliver value to patients
·      (9:16): Commercialisation strategy across key regions
·      (11:23): Additional assets in the PIQ pipeline
·      (12:36): What investors can expect over the next 12 months

Note: This interview was recorded on 3 July 2025.

January review

Julia Lee
January 27, 2017

Superannuation Reforms

Bell Direct
January 16, 2017

Market Update

Julia Lee
January 16, 2017

Market Update

Julia Lee
January 13, 2017

Market Update 12 Jan

Julia Lee
January 12, 2017

Market Update

Julia Lee
January 11, 2017

Market Update

Julia Lee
January 9, 2017

Market Update

Julia Lee
January 6, 2017

Market Update

Julia Lee
January 5, 2017